 |
Prospector
Profile
07.1671
|
| |
| Sinobiomed, Inc. |
NAICS |
541710 |
| Zhong-Huang Plaza
Shanghai, China 200080 |
Description |
Biotechnology |
| 011-86-21-56969868 |
Employees |
0 |
| http://www.sinobiomed.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.1120 |
| |
Assets |
(mil) |
0.0000 |
| |
Liability |
(mil) |
0.0620 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Sinobiomed Inc. reported a net loss of $1.2 million on sales of $4.1 million for the third quarter ended Sept. 30, 2007, compared with a net loss of $376,202 on sales of $183,076 in the third quarter of 2006. The company's consolidated balance sheet at Sept. 30, 2007, showed $16.7 million in total assets, $22.9 million in total liabilities, and $52,146 in minority interest, resulting in a $6.2 million total shareholders' deficit. At Sept. 30, 2007, the company's consolidated balance sheet also showed strained liquidity with $9.3 million in total current assets available to pay $22.7 million in total current liabilities.
|
| |
|
Intellectual Property:
The Company protects the technology important to its business by filing PRC patent applications and relying on trade secret and pharmaceutical regulatory protection. In addition to patents, the Company relies on trade secrets and proprietary know-how to protect intellectual property. [SEC Filing 10-KSB 03-28-07]
|
| |
|
Description:
The Company is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines.
|
| |
|
Officers:
Ban-Jun Yang (Pres., CEO & Dir.); Ka Yu (Sec., Treas. & Dir.); Asher Zwebner (CFO); Robert Ip (Dir.); Chris Metcalf (Dir.); Dr. Kim Kiat Ong (Dir.)
|
| |
|
Auditor:
Schumacher & Associates, Inc.
|
| |
|
Securities:
Common Stock-Symbol SOBM.OB; OTC BB;
130,763,748 common shares outstanding as of November 19, 2007.
|
| |
| |
| |
| return to main page |
|
|
